The phase 3 PACE-B trial demonstrated that stereotactic body radiation therapy is noninferior to conventional radiation therapy for low- and favorable-intermediate-risk prostate cancer with respect to biochemical clinical failure. Stereotactic body radiation therapy is noninferior to conventional external beam radiation therapy for low- and favorable-intermediate-risk prostate cancer.
Three radiation oncologists describe living through cyberattacks that paralyzed their clinics. They urge all clinicians to make plans to keep services running so that patients don t miss out on treatment.
Do we need a new standard of care for colorectal cancer? | Vermont Business Magazine vermontbiz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vermontbiz.com Daily Mail and Mail on Sunday newspapers.